Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030

  • ID: 3927802
  • Report
  • Region: Global
  • 314 Pages
  • Roots Analysis
1 of 5
The Innovation in This Emerging Field Is Largely Driven by Smaller Firms, Specifically Start-Ups

FEATURED COMPANIES

  • Abramson Cancer Center
  • CANCER RESEARCH UK
  • Ehime University Hospital
  • Kiromic
  • OrbiMed
  • Swissmedic
  • MORE
The Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030 offers a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of products in the therapeutic vaccines segment of the immuno-oncology domain. Currently, there are five types of such vaccines; these are dendritic cell vaccines, tumor cell vaccines, antigen / peptide vaccines, DNA vaccines and anti-idiotypic vaccines. This report is focused on the recent developments and the future potential of dendritic cell vaccines (dendritic cell loaded vaccines) and tumor cell vaccines (tumor cell loaded vaccines).

During the course of our study, we identified a variety of dendritic cell and tumor cell cancer vaccines across various stages of development. More than 75% of these product candidates are currently in the clinical stages of development. With a rich development pipeline, this segment of the immunotherapy market has managed to capture the interest of several strategic investors and venture capital firms. During our research, we observed that over USD 1.5 billion has already been invested in this domain in past five years. Owing to the existing unmet demand for safe and effective cancer therapies and given the innate advantages of immunotherapies, we believe that dendritic cell and tumor cell cancer vaccines present lucrative opportunities for both therapy developers and investors alike.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. For this purpose, we took into consideration the following parameters:

- The dendritic cell and tumor cell vaccines pipeline, including marketed, clinical and preclinical therapies, in terms of phase of development, key players, type of donor and target indications.
- The existing and emerging technology platforms used for the development of innovative variants of cancer vaccines.
- The partnerships that have taken place in the recent past covering clinical trial collaborations, research collaborations, manufacturing and services agreements, license agreements specific to technology platforms and agreements related to the co-development and co-commercialization of promising candidates.
- Various investments and grants received by companies focused in this area including capital raised from IPOs and subsequent offerings.
- The performance of competing drug classes, complex manufacturing processes, batch-wise variability and other inherent threats to growth of the market in the short and long term.

The report offers comprehensive profiles highlighting developmental history, clinical trial details and key clinical results as well as the future market opportunity for marketed and late stage (phase III) candidates. This opportunity is linked to the target consumer segments, likely adoption rate and expected pricing. We have provided an estimate of the size of the market in the short-mid-term and long term for the period between 2016 and 2030. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base, and optimistic tracks of the market’s evolution.

Example Highlights

- Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.
- 86% of the pipeline therapies are being developed as treatment options for solid tumors, including lung cancers, glioblastoma, prostate cancer and melanoma. In fact, two of the three marketed dendritic cell vaccines, PROVENGE® and TAPCells® (Chile), are approved for treatment of prostate cancer.  In addition, a dendritic cell vaccine is also being developed as a first targeted therapy for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer with poor survival rates.
- The innovation in this emerging field is largely driven by smaller firms, specifically start-ups. Notable examples of small firms and start-ups include (in alphabetical order) Asterias Biotherapeutics, AVAX Technologies, DCPrime, Gradalis, Heat Biologics, ImmunoCellular Therapeutics, Immunicum,  MolecuVax, Northwest Biotherapeutics, PDC*line Pharma, Pique Therapeutics, Regeneus, Tessa Therapeutics, Vaccinogen and XEME Biopharma. These companies have developed technology platforms that enhance the efficacy of therapeutic vaccines. Examples of some novel technology platforms include (in alphabetical order) AGGREGON™, DCOne®, ImPACT and Vigil®.
- Several strategic investors and venture capitalists have strongly backed the potential offered by this domain. We identified over 125 instances of funding over the last few years. The total amount invested has been close to USD 2.0 billion; of this, USD 1.5 billion came during the last five years alone.
- Several agreements have been inked amongst the stakeholders over past few years. We captured over 100 partnerships that are categorized across product development / commercialization agreement, manufacturing / supply agreement, service agreement, technology acquisition / licensing, clinical trial collaboration, research collaboration and others. Of these, clinical trial collaborations and technology acquisition / licensing together account for close to 50% share.
- Prominent academic players, including (in alphabetical order) the Dana-Farber Cancer Institute, King’s College London, Mary Crowley Research Cancer Center, MD Anderson Cancer Center, University of Chile, and University of Pennsylvania, have entered into research collaborations with industry players to conduct further research for the improvement of existing therapies and the development of novel technologies.
- Overall, the dendritic cell and tumor cell cancer vaccines market is expected to grow at a healthy annual rate of 20.7% till 2030. Dendritic cell vaccines are likely to garner the most attention in near future. Post 2020, we expect tumor cell vaccines to begin to actively contribute to the market’s revenues primarily driven by approval of Vigil®.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abramson Cancer Center
  • CANCER RESEARCH UK
  • Ehime University Hospital
  • Kiromic
  • OrbiMed
  • Swissmedic
  • MORE
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Cancer: An Overview
3.2. Current Statistics and Global Burden of the Disease
3.3. The Four Pillars of Cancer Therapy
3.4. Immunotherapy: Gaining Strong Foothold
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Therapeutic Antibodies
3.5.4.1.1. Monoclonal Antibodies
3.5.4.1.2. Bispecific Antibodies
3.5.4.1.3. Antibody Drug Conjugates
3.5.4.1.4. Engineered Antibodies
3.5.4.2. Cytokines
3.5.4.3. Cell Based Therapies
3.5.4.4. Immune Checkpoint Inhibitors
3.5.4.5. Cancer Vaccines

4. Cancer Vaccines
4.1. Vaccines: An Overview
4.2. Cancer Vaccines: An Overview
4.2.1. Cancer Vaccines: History of Development
4.2.2. Tumor Evasion from Immune Surveillance
4.2.3. Potential Targets
4.3. Types of Cancer Vaccines
4.3.1. Classification Based on Type of Cancer Vaccine
4.3.1.1. Prophylactic (Preventive) Vaccines
4.3.1.2. Therapeutic (Treatment) Vaccines
4.3.2. Classification Based on Type of Donor
4.3.2.1. Autologous Cancer Vaccines
4.3.2.2. Allogeneic Cancer Vaccines
4.3.3. Classification Based on Composition
4.3.3.1. Antigen Vaccines
4.3.3.2. Anti- Idiotypic Vaccines
4.3.3.3. DNA Vaccines
4.3.3.4. Dendritic Cell Vaccines
4.3.3.5. Tumor Cell Vaccines
4.4. Challenges Associated with Cancer Vaccines

4.5. Regulatory Guidelines for Therapeutic Cancer Vaccines
4.5.1. Considerations for All Three Clinical Trial Phases
4.5.1.1. Selection of Patient Population on the Basis of Disease Setting, Tumor Heterogeneity and Target Antigen
4.5.1.2. Monitoring the Immune Response
4.5.1.3. Progression / Recurrence of the Disease Post Treatment with Cancer Vaccines
4.5.2. Considerations for Early Clinical Trials
4.5.2.1. Starting Dose and Dosing Schedule
4.5.2.2. Dose Escalation
4.5.2.3. Single-arm versus Randomized Phase II Trials
4.5.3. Considerations for Late Phase Clinical Trials
4.5.3.1. Safety Profile from Early Phase Clinical Trials
4.5.3.2. Endpoints
4.5.3.3. Superiority Versus Non- Inferiority Design
4.5.3.4. Selection of Control
4.5.3.5. Delayed Vaccine Effect
4.5.3.6. Autologous Vaccine Trials
4.5.4. Accelerated Approval Regulations

5. Market Overview
5.1. Chapter Overview
5.2. Dendritic Cell and Tumor Cell Cancer Vaccines: A Robust Pipeline
5.3. Pipeline Analysis
5.3.1. Cancer Vaccines: Distribution by Type of Cancer Vaccine
5.3.2. Cancer Vaccines: Distribution by Phase of Development
5.3.3. Cancer Vaccines: Distribution by Type of Oncological Indication
5.3.3.1. Cancer Vaccines: Distribution by Hematological Cancers
5.3.3.2. Cancer Vaccines: Distribution by Non-Hematological Cancers
5.3.4. Cancer Vaccines: Distribution by Type of Donor

6. Dendritic Cancer Cell Vaccines
6.1. Chapter Overview
6.2. Dendritic Cell Cancer Vaccines: An Introduction
6.3. Dendritic Cell Cancer Vaccines: Mechanism of Action
6.4. Dendritic Cell Cancer Vaccines: Pipeline

6.5. Dendreon Corporation (A Subsidiary of Valeant Pharmaceuticals)
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Technology Overview
6.5.3.1.  Antigen Delivery Cassette® Technology
6.5.4. Patent Portfolio
6.5.5. Manufacturing Facilities
6.5.6. Product Portfolio
6.5.6.1. PROVENGE® / Sipuleucel-T
6.5.6.1.1. Product Overview
6.5.6.1.2. History of Development
6.5.6.1.3. Dosage Regimen
6.5.6.1.4. Historical Sales
6.5.6.1.5. Treatment Cost and Reimbursement
6.5.6.1.6. Current Status of Development
6.5.6.1.7. Clinical Trials
6.5.6.1.8. Key Clinical Trial Results

6.6. JW CreaGene
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.2.1. DC Technology
6.6.3. Patent Portfolio
6.6.4. Product Portfolio
6.6.4.1. CreaVax-RCC®
6.6.4.1.1. Product Overview
6.6.4.1.2. Dosage Regimen
6.6.4.1.3. Clinical Trials
6.6.4.2. CreaVax-HCC
6.6.4.2.1. Product Overview
6.6.4.2.2. Current Status of Development
6.6.4.2.3. Clinical Trials

6.7. Oncobiomed
6.7.1. Company Overview
6.7.2. Technology Overview
6.7.2.1. TAPCells® Technology
6.7.3. Patent Portfolio
6.7.4. Product Portfolio
6.7.4.1. TAPCells®
6.7.4.1.1. Product Overview
6.7.4.1.2. Dosage Regimen
6.7.4.1.3. Clinical Trials

6.8. Argos Therapeutics
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Technology Overview
6.8.3.1. Arcelis® Technology
6.8.4. Patent Portfolio
6.8.5. Manufacturing Facilities
6.8.6. Product Portfolio
6.8.6.1. AGS-003
6.8.6.1.1. Product Overview
6.8.6.1.2. History of Development
6.8.6.1.3. Dosage Regimen
6.8.6.1.4. Current Status of Development
6.8.6.1.5. Clinical Trials
6.8.6.1.6. Key Clinical Trial Results

6.9. ImmunoCellular Therapeutics
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Technology Overview
6.9.3.1. Dendritic Cell (DC)-Based Immunotherapy
6.9.3.2. Stem-to-T-cell Program
6.9.4. Patent Portfolio
6.9.5. Manufacturing Facilities
6.9.6. Product Portfolio
6.9.6.1. ICT-107
6.9.6.1.1. Product Overview
6.9.6.1.2. History of Development
6.9.6.1.3. Dosage Regimen
6.9.6.1.4. Current Status of Development
6.9.6.1.5. Clinical Trials
6.9.6.1.6. Key Clinical Trial Results

6.10. Northwest Biotherapeutics
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. Technology Overview
6.10.3.1. DCVax® Technology
6.10.4. Patent Portfolio
6.10.5. Manufacturing Facilities
6.10.6. Product Portfolio
6.10.6.1. DCVax®-L
6.10.6.1.1. Product Overview
6.10.6.1.2. History of Development
6.10.6.1.3. Dosage Regimen
6.10.6.1.4. Current Status of Development
6.10.6.1.5. Clinical Trials
6.10.6.1.6. Key Clinical Trial Results

6.11. SOTIO (Acquired by PPF Group)
6.11.1. Company Overview
6.11.2. Financial Performance
6.11.3. Technology Overview
6.11.3.1. Active Cellular Immunotherapy Multiple Antigen Presentation
6.11.4. Patent Portfolio
6.11.5. Manufacturing Facilities
6.11.6. Product Portfolio
6.11.6.1. DCVAC/PCa
6.11.6.1.1. Product Overview
6.11.6.1.2. History of Development
6.11.6.1.3. Dosage Regimen
6.11.6.1.4. Current Status of Development
6.11.6.1.5. Clinical Trials
6.11.6.1.6. Key Clinical Results

6.12. Dendritic Cell Cancer Vaccines: Key Drivers and Restraints

7. Tumor Cell Cancer Vaccines
7.1. Chapter Overview
7.2. Tumor Cell Cancer Vaccines: An Overview
7.3. Tumor Cell Cancer Vaccines: Mechanism of Action
7.4. Tumor Cell Cancer Vaccines: Pipeline

7.5. Vaccinogen
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Technology Overview
7.5.3.1. OncoVAX® Technology Platform
7.5.3.2. HuMabs
7.5.3.3. DiCAST
7.5.4. Patent Portfolio
7.5.5. Manufacturing Facilities
7.5.6. Product Portfolio
7.5.6.1. OncoVAX®
7.5.6.1.1. Product Overview
7.5.6.1.2. History of Development
7.5.6.1.3. Production Process
7.5.6.1.4. Dosage Regimen
7.5.6.1.5. Current Status of Development
7.5.6.1.6. Clinical Trials
7.5.6.1.7. Key Clinical Trial Results

7.6. Gradalis
7.6.1. Company Overview
7.6.2. Technology Overview
7.6.2.1. Vigil® Platform
7.6.3. Patent Portfolio
7.6.4. Product Portfolio
7.6.4.1. Vigil®
7.6.4.1.1. Product Overview
7.6.4.1.2. History of Development
7.6.4.1.3. Production Process
7.6.4.1.4. Dosage Regimen
7.6.4.1.5. Current Status of Development
7.6.4.1.6. Clinical Trials
7.6.4.1.7. Key Clinical Trial Results

7.7. Case Study: HyperAcute Cellular Immunotherapy
7.7.1. NewLink Genetics
7.7.1.1. Company Overview
7.7.1.2. Financial Performance
7.7.1.3. Technology Overview
7.7.1.3.1. HyperAcute® Cellular Immunotherapy
7.7.1.4. Patent Portfolio
7.7.1.5. Manufacturing Facilities
7.7.1.6. Product Portfolio
7.7.1.6.1. Algenpantucel- L
7.7.1.6.2. Tergenpumatucel-L

7.8. Tumor Cell Vaccines: Drivers and Restraints

8. Key Technologies
8.1. Chapter Overview
8.2. Asterias Biotherapeutics
8.2.1. Company Overview
8.2.2. Technology Platforms
8.2.2.1. Asterias’ Cell Therapy Platform
8.2.2.2. Pluripotent Stem Cell Platform
8.2.3. Pipeline

8.3. AVAX Technologies
8.3.1. Company Overview
8.3.2. Technology Platforms
8.3.2.1. Autologous Cell (AC) Vaccine® Technology
8.3.3. Pipeline

8.4. DCPrime
8.4.1. Company Overview
8.4.2. Technology Platforms
8.4.2.1. DCOne®
8.4.3. Pipeline

8.5. Heat Biologics
8.5.1. Company overview
8.5.2. Technology Platforms
8.5.2.1. ImPACT
8.5.2.2. ComPACT
8.5.3. Pipeline

8.6. Immunicum
8.6.1. Company Overview
8.6.2. Technology Platforms
8.6.2.1. COMBIG
8.6.2.1.1. INTUVAX®
8.6.2.1.2. SUBCUVAX®
8.6.3. Pipeline

8.7. XEME Biopharma
8.7.1. Company Overview
8.7.2. Technology Platforms
8.7.2.1. AGGREGON™
8.7.3. Pipeline

9. Venture Capital Funding
9.1. Chapter Overview
9.2. Types of Funding
9.3. Cancer Vaccines Market: Funding Instances
9.4. Cancer Vaccines Market: Rising Venture Capital Interest
9.5. Distribution of Funding Instances by Type of Funding
9.6. Leading Players: Distribution by Number of Funding Instances
9.7. Cancer Vaccines: Analysis by Type of Investment and Amount Invested

10. Partnerships And Collaborations
10.1. Chapter Overview
10.2. Partnerships Models / Agreements
10.3. Cancer Vaccines: List of Partnerships
10.4. Cancer Vaccines: Growing Trend of Partnerships

11. Market Forecast
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Forecast Methodology
11.4. Overall Cancer Vaccines Market, 2016 - 2030
11.4.1. Overall Cancer Vaccines Market: Distribution by Type of Vaccine

11.5. Individual Therapy Forecast
11.5.1. PROVENGE® (Dendreon Corporation / Valeant Pharmaceuticals)
11.5.1.1. Target Patient Population
11.5.1.2. Sales Forecast

11.5.2. DCVax®-L / DCVax-Brain (Northwest Biotherapeutics)
11.5.2.1. Target Patient Population
11.5.2.2. Sales Forecast

11.5.3. AGS-003 (Argos Therapeutics)
11.5.3.1. Target Patient Population
11.5.3.2. Sales Forecast

11.5.4. DCVAC/PCa (SOTIO)
11.5.4.1. Target Patient Population
11.5.4.2. Sales Forecast

11.5.5. Vigil® (Gradalis)
11.5.5.1. Target Patient Population
11.5.5.2. Sales Forecast

11.5.6. AST-VAC1 / GRNVAC1 (Asterias Biotherapeutics)
11.5.6.1. Target Patient Population
11.5.6.2. Sales Forecast

11.5.7. M-VAX (AVAX Technologies)
11.5.7.1. Target Patient Population
11.5.7.2. Sales Forecast

11.5.8. ICT-107 (ImmunoCellular Therapeutics)
11.5.8.1. Target Patient Population
11.5.8.2. Sales Forecast

11.5.9. OncoVAX® (Vaccinogen)
11.5.9.1. Target Patient Population
11.5.9.2. Sales Forecast

11.5.10. MX-225 (Aurora Biopharma)
11.5.10.1. Target Patient Population
11.5.10.2. Sales Forecast

12. Conclusion
12.1. A Robust Pipeline Dominated by Dendritic Cell Vaccine Candidates
12.2. Allogeneic Off-the-Shelf Vaccines Being Developed to Overcome Manufacturing Challenges Associated with Personalized Autologous Therapies
12.3. An Active Market Segment Primarily Driven by Start-Ups and Small Companies
12.4. Broad Spectrum Therapies that are Currently Focused Mainly on Lung Cancer and Melanoma
12.5. Innovative Technology Platforms are a Key Enabler
12.6. Lucrative Future Opportunity Despite the Limited Success of Currently Marketed Therapies

13. Interview Transcripts

14. Appendix: Tabulated Data

15.  Appendix: List Of Companies And Organizations

List of Figures

Figure 3.1 Global Cancer Incidence: Distribution by Type of Cancer

Figure 3.2 Lung Cancer: Estimated New Cases in 2015 (Thousands)

Figure 3.3 Breast Cancer: Estimated New Cases in 2015 (Thousands)

Figure 3.4 Colorectal Cancer: Estimated New Cases in 2015 (Thousands)

Figure 3.5 The Four Pillars of Cancer Therapy

Figure 3.6 Differences between Active and Passive Immunotherapy

Figure 3.7 Differences between Specific and Non-Specific Immunotherapy

Figure 3.8 Components of ADCs

Figure 4.1 APC-T-cell Interaction: Fate of T-cells

Figure 4.2 Cancer Vaccines: Historical Milestones

Figure 4.3 Interaction between Tumor Cells and the Immune System

Figure 5.1 Cancer Vaccines: Distribution by Type of Vaccine

Figure 5.2 Cancer Vaccines: Distribution by Phase of Development

Figure 5.3 Cancer Vaccines: Distribution by Phase of Development (Marketed / PIII / PII / PI / Preclinical)

Figure 5.4 Cancer Vaccines: Distribution by Therapeutic Area

Figure 5.5 Cancer Vaccines: Distribution by Hematological Cancers and Type of Vaccine

Figure 5.6 Cancer Vaccines: Distribution by Non-Hematological Cancers and Type of Vaccine

Figure 5.7 Cancer Vaccines: Distribution by Type of Donor

Figure 6.1 Stages of Immunostimulation by Dendritic Cells

Figure 6.2 Dendreon Corporation: Revenues, 2010-2013 (USD Million)

Figure 6.3 PROVENGE: Historical Timeline

Figure 6.4 PROVENGE: Historical Sales, 2011-2015 (USD Million)

Figure 6.5 Argos Therapeutics: Revenues, 2012-2016 (USD Million)

Figure 6.6 Argos Therapeutics: Funding Instances

Figure 6.7 AGS-003: Historical Timeline

Figure 6.8 ImmunoCellular Therapeutics: Funding Instances (USD Million)

Figure 6.9 DC-based Immunotherapeutics: Manufacturing Process

Figure 6.10 ICT-107: Historical Timeline

Figure 6.11 Northwest Biotherapeutics: Revenue, 2011-2015 (USD Million)

Figure 6.12 Northwest Biotherapeutics: Funding Instances (USD Million)

Figure 6.13 DCVax-L: Historical Timeline

Figure 6.14 PPF Group: Revenues, 2011-2015 (EUR Billion)

Figure 6.15 DCVAC/PCa: Historical Timeline

Figure 6.16 Dendritic Cell Cancer Vaccines: Key Drivers and Restraints

Figure 7.1 Vaccinogen: Funding Instances (USD Million)

Figure 7.2 OncoVAX: Historical Timeline

Figure 7.3 OncoVAX: Production Process

Figure 7.4 OncoVAX: Dosage Regimen

Figure 7.5 Vigil: Historical Timeline

Figure 7.6 NewLink Genetics: Revenues, 2012-2016 (USD Million)

Figure 7.7 NewLink Genetics: Funding Instances (USD Million)

Figure 7.8 Algenpantucel- L: Historical Timeline

Figure 7.9 Tumor Cell Cancer Vaccines: Key Drivers and Restraints

Figure 8.1 DCOne: Key Steps Involved

Figure 8.2 AGGREON: Proposed Mechanism of Action

Figure 9.1 Cumulative Funding Instances, Pre-2009-2016

Figure 9.2 Cumulative Funding Amount, Pre-2009-2016 (USD Million)

Figure 9.3 Funding Instances: Distribution by Type, Pre-2009-2016

Figure 9.4 Funding Instances: Distribution by Total Amount Invested, Pre-2009-2016 (USD Million)

Figure 9.5 Leading Players: Distribution by Number of Funding Instances

Figure 9.6 Funding Instances: Distribution by Amount Invested by Type of Funding (USD Million)

Figure 10.1 Cancer Vaccines: Cumulative Trend of Partnerships (Pre-2010-2016)

Figure 10.2 Cancer Vaccines: Distribution by Type of Partnership

Figure 10.3 Cancer Vaccines: Leading Players by Partnerships

Figure 11.1 Overall Dendritic Cell and Tumor Cell Cancer Vaccines Market (USD Million), 2016-2030

Figure 11.2 Overall Dendritic Cell and Tumor Cell Cancer Vaccines Market: Distribution by Type of Cancer Vaccine (USD Million), 2016-2030

Figure 11.3 Evolution of Dendritic Cell and Tumor Cell Cancer Vaccine Market: 2020, 2025 & 2030 (Base Scenario)

Figure 11.4 PROVENGE Sales Forecast, 2016-2030: Base Scenario (USD Million)

Figure 11.5 DCVax-L Sales Forecast, 2017-2030: Base Scenario (USD Million)

Figure 11.6 AGS-003 Sales Forecast, 2018-2030: Base Scenario (USD Million)

Figure 11.7 DCVAC/PCa Sales Forecast, 2020-2030: Base Scenario (USD Million)

Figure 11.8 Vigil Sales Forecast, 2021-2030: Base Scenario (USD Million)

Figure 11.9 AST-VAC1 Sales Forecast, 2022-2030: Base Scenario (USD Million)

Figure 11.10 M-VAX Sales Forecast, 2022-2030: Base Scenario (USD Million)

Figure 11.11 ICT-107 Sales Forecast, 2023-2030: Base Scenario (USD Million)

Figure 11.12 OncoVAX Sales Forecast, 2025-2030: Base Scenario (USD Million)

Figure 11.13 MX-225 Sales Forecast, 2026-2030: Base Scenario (USD Million)

Figure 12.1 Dendritic Cell and Tumor Cell Cancer Vaccines: Development Landscape

Figure 12.2 Dendritic Cell Cancer Vaccines: Developer Landscape

Figure 12.3 Tumor Cell Cancer Vaccines: Developer Landscape

Figure 12.4 Dendritic Cell and Tumor Cell Cancer Vaccines: Analysis by Cancer Type

Figure 12.5 Dendritic Cell and Tumor Cell Cancer Vaccines: Technology Landscape

Figure 12.6 Dendritic Cell and Tumor Cell Cancer Vaccines Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2030 (USD Million)

List of Tables

Table 4.1 Cancer Vaccines: Potential Antigen Targets

Table 5.1 Cancer Vaccines: Pipeline

Table 5.2 Cancer Vaccines: Pipeline (Other Vaccines)

Table 6.1 Dendritic Cell Cancer Vaccines: Pipeline

Table 6.2 Dendreon Corporation: Patent Portfolio

Table 6.3 Dendreon Corporation: Cancer Vaccine Portfolio

Table 6.4 PROVENGE: Current Status of Development

Table 6.5 PROVENGE: Clinical Trials

Table 6.6 PROVENGE: Phase III Clinical Trial Endpoints (NCT00779402, NCT00065442, NCT01133704, NCT00005947)

Table 6.7 PROVENGE: Phase II Clinical Trial Endpoints (NCT01431391, NCT01338012, NCT01487863, NCT00715104)

Table 6.8 PROVENGE: Phase II Clinical Trial Endpoints (NCT01477749, NCT01981122, NCT00901342, NCT01804465)

Table 6.9 PROVENGE: Phase II Clinical Trial Endpoints (NCT00715078, NCT01706458, NCT02159950, NCT00849290, NCT01833208)

Table 6.10 JW CreaGene: Patent Portfolio

Table 6.11 JW CreaGene: Cancer Vaccine Portfolio

Table 6.12 CreaVax-RCC: Clinical Trials

Table 6.13 CreaVax-HCC: Current Status of Development

Table 6.14 CreaVax-HCC: Clinical Trials

Table 6.15 CreaVax-HCC: Clinical Trial Endpoints

Table 6.16 Oncobiomed: Cancer Vaccine Portfolio

Table 6.17 TAPCells: Clinical Trials and Results

Table 6.18 Argos Therapeutics: Patent Portfolio

Table 6.19 Argos Therapeutics: Cancer Vaccine Portfolio

Table 6.20 AGS-003: Current Status of Development

Table 6.21 AGS-003: Clinical Trials

Table 6.22 AGS-003: Clinical Trial Endpoints

Table 6.23 ImmunoCellular Therapeutics: Patent Portfolio

Table 6.24 ImmunoCellular Therapeutics: Cancer Vaccine Portfolio

Table 6.25 ICT-107: Phases of Treatment Regimen

Table 6.26 ICT-107: Current Status of Development

Table 6.27 ICT-107: Clinical Trials

Table 6.28 ICT-107: Clinical Trial Endpoints

Table 6.29 Northwest Biotherapeutics: Patent Portfolio

Table 6.30 Northwest Biotherapeutics: Cancer Vaccine Portfolio

Table 6.31 DCVax-L: Current Status of Development

Table 6.32 DCVax-L: Clinical Trials

Table 6.33 DCVax-L: Clinical Trial Endpoints

Table 6.34 SOTIO: Patent Portfolio

Table 6.35 SOTIO: Cancer Vaccine Portfolio

Table 6.36 DCVAC/PCa: Current Status of Development

Table 6.37 DCVAC/PCa: Clinical Trials

Table 6.38 DCVAC/PCa: Clinical Trial Endpoints (NCT02111577, NCT02105675, NCT02107391)

Table 6.39 DCVAC/PCa: Clinical Trial Endpoints (NCT02107430, NCT02107404, NCT02137746)

Table 7.1 Tumor Cell Cancer Vaccines: Pipeline

Table 7.2 Vaccinogen: Patent Portfolio

Table 7.3 Vaccinogen: Cancer Vaccine Portfolio

Table 7.4 OncoVAX: Current Status of Development

Table 7.5 OncoVAX: Clinical Trials

Table 7.6 OncoVAX: Ongoing Clinical Trials

Table 7.7 OncoVAX: Results of Completed Clinical Trials

Table 7.8 Gradalis: Patent Portfolio

Table 7.9 Gradalis: Cancer Vaccine Portfolio

Table 7.10 Vigil: Current Status of Development

Table 7.11 Vigil: Clinical Trials

Table 7.12 Vigil: Clinical Trial Endpoints (Ovarian Cancer)

Table 7.13 Vigil: Clinical Trial Endpoints (Ewing’s Sarcoma)

Table 7.14 Vigil: Clinical Trial Endpoints (NSCLC)

Table 7.15 Vigil: Clinical Trial Endpoints (Melanoma)

Table 7.16 NewLink Genetics: Patent Portfolio

Table 7.17 NewLink Genetics: Cancer Vaccine Portfolio

Table 7.18 Algenpantucel-L: Clinical Trials

Table 7.19 Algenpantucel-L: Clinical Trial Endpoints

Table 7.20 Tergenpumatucel-L: Clinical Trials

Table 7.21 Tergenpumatucel-L: Clinical Trial Endpoints

Table 8.1 Asterias Biotherapeutics: Cancer Vaccine Portfolio

Table 8.2 AVAX Technologies: Cancer Vaccine Portfolio

Table 8.3 DCPrime: Cancer Vaccine Portfolio

Table 8.4 Heat Biologics: Cancer Vaccine Portfolio

Table 8.5 Immunicum: Cancer Vaccine Portfolio

Table 8.6 XEME Biopharma: Cancer Vaccine Portfolio

Table 9.1 Cancer Vaccines: Funding Instances

Table 9.2 Cancer Vaccines Market: Types of Funding Instances, Pre-2009-2016

Table 10.1 Cancer Vaccines: Partnerships

Table 11.1 Cancer Vaccines: Expected Timelines of Marketed / Late Stage Therapies

Table 11.2 PROVENGE: Target Patient Population

Table 11.3 DCVax-L: Target Patient Population

Table 11.4 AGS-003: Target Patient Population

Table 11.5 DCVAC/PCa: Target Patient Population

Table 11.6 Vigil: Target Patient Population

Table 11.7 AST-VAC1: Target Patient Population

Table 11.8 M-VAX: Target Patient Population

Table 11.9 ICT-107: Target Patient Population

Table 11.10 OncoVAX: Target Patient Population

Table 11.11 MX-225: Target Patient Population

Table 14.1 Global Cancer Incidence: Distribution by Type of Cancer

Table 14.2 Lung Cancer: Estimated New Cases in 2015 (Thousands)

Table 14.3 Breast Cancer: Estimated New Cases in 2015 (Thousands)

Table 14.4 Colorectal Cancer: Estimated New Cases in 2015 (Thousands)

Table 14.5 Cancer Vaccines: Distribution by Type of Vaccine

Table 14.6 Cancer Vaccines: Distribution by Phase of Development

Table 14.7 Cancer Vaccines: Distribution by Phase of Development (Marketed / PIII / PII / PI / Preclinical)

Table 14.8 Cancer Vaccines: Distribution by Therapeutic Area

Table 14.9 Cancer Vaccines: Distribution by Hematological Cancers and Type of Vaccine

Table 14.10 Cancer Vaccines: Distribution by Non-Hematological Cancers and Type of Vaccine

Table 14.11 Cancer Vaccines: Distribution by Type of Donor

Table 14.12 Dendreon Corporation: Revenues, 2010-2013 (USD Million)

Table 14.13 PROVENGE: Historical Sales, 2011-2015 (USD Million)

Table 14.14 Argos Therapeutics: Revenues, 2012-2016 (USD Million)

Table 14.15 Argos Therapeutics: Funding Instances (USD Million)

Table 14.16 ImmunoCellular Therapeutics: Funding Instances (USD Million)

Table 14.17 Northwest Biotherapeutics: Revenue, 2011-2015 (USD Million)

Table 14.18 Northwest Biotherapeutics: Funding Instances (USD Million)

Table 14.19 PPF Group: Revenues, 2011-2015 (EUR Billion)

Table 14.20 Vaccinogen: Funding Instances (USD Million)

Table 14.21 NewLink Genetics: Revenues, 2012-2016 (USD Million)

Table 14.22 NewLink Genetics: Funding Instances (USD Million)

Table 14.23 Cumulative Funding Instances, Pre-2009-2016

Table 14.24 Cumulative Funding Amount, Pre-2009-2016 (USD Million)

Table 14.25 Funding Instances: Distribution by Type, Pre-2009-2016

Table 14.26 Funding Instances: Distribution by Total Amount Invested, Pre-2009-2016 (USD Million)

Table 14.25 Leading Players: Distribution by Number of Funding Instances

Table 14.26 Cancer Vaccines: Cumulative Trend of Partnerships (Pre-2010-2016)

Table 14.27 Cancer Vaccines: Distribution by Type of Partnership

Table 14.28 Cancer Vaccines: Leading Players by Partnerships

Table 14.29 Overall Dendritic Cell and Tumor Cell Cancer Vaccines Market (USD Million), 2016-2030

Table 14.30 Overall Dendritic Cell and Tumor Cell Cancer Vaccine Market: Distribution by Type of Cancer Vaccine (USD Million), 2016-2030

Table 14.31 PROVENGE Sales Forecast, 2016-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.32 DCVax-L Sales Forecast, 2017-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.33 AGS-003 Sales Forecast, 2018-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.34 DCVAC/PCa Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.35 Vigil Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.36 AST-VAC1 Sales Forecast, 2022-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.37 M-VAX Sales Forecast, 2022-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.38 ICT-107 Sales Forecast, 2023-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.39 OncoVAX Sales Forecast, 2025-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)

Table 14.40 MX-225 Sales Forecast, 2026-2030: Base Scenario (USD Million)

Table 14.41 Dendritic Cell and Tumor Cell Cancer Vaccines Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2030 (USD Million)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abramson Cancer Center
  • CANCER RESEARCH UK
  • Ehime University Hospital
  • Kiromic
  • OrbiMed
  • Swissmedic
  • MORE
Cancer is an extremely complex disease and medical science is still trying to understand the numerous factors responsible for its origin, propagation, spread (metastasis) and relapse. In 2016, an estimated 1.7 million new cancer cases were reported in the US alone. Furthermore, as projected by the World Health Organization (WHO), the annual incidence of cancer worldwide is expected to rise to 24 million by 2035.

Currently, there is a huge unmet need for advanced and efficient treatment interventions for cancer. Standard approaches that are currently employed to treat cancer include surgery, radiation therapy and chemotherapy. Although all the three approaches are recognized as the current standard of care in cancer treatment, there are some risks and drawbacks associated with these methods.

Many pharmaceutical companies are working on identifying ways to improve these treatment methods, as well as develop new cancer therapies. One of the current focus areas is immunotherapy; it makes use of the body’s own immune system, or its components, to fight cancer. So far, antibody based therapeutics, including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs) and antibody drug conjugates (ADCs), have had significant success as targeted anti-cancer therapies. Apart from antibody based therapies, there are other classes of immunotherapeutics that have been / are being developed to manage and treat cancer; these include immune checkpoint inhibitors (ICIs), therapeutic cancer vaccines and other whole cell based therapies.

The USFDA has approved cancer prevention vaccines (the human papillomavirus (HPV) vaccine and hepatitis B vaccine (HBV)) that prevent infection with cancer-causing viruses. Gardasil®, Gardasil 9® and Cervarix® are approved for the prevention of HPV-caused cancers whereas Engerix-B®, Recombivax HB®, Twinrix® and Pediarix® are approved for the prevention of chronic HBV infection. Although, preventive vaccines offer several benefits, the fact that viruses do not cause most cancers cannot be overlooked. Therefore, several companies are developing therapeutic vaccines that target specific cancers.

As of now, there are three marketed therapeutic cancer vaccines commercially available in different geographies; these include PROVENGE® (US), CreaVax-RCC® (South Korea) and TAPCells® (Chile). Despite the limited success of PROVENGE®, the first marketed dendritic cell vaccine, several stakeholders are actively engaged in the development of dendritic cell and tumor cell-based vaccines.

Research Methodology

Most of the data presented in this report has been gathered through secondary research. For most of our projects, we also conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and wearable types. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analyst's opinion reports

While the focus has been on forecasting the market over the coming 14 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the market developed from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the report. It offers a high level view on evolution of the dendritic cell and tumor cell cancer vaccines market in the mid to long term.

Chapter 3 provides information on the rising global burden of cancer and the various available therapeutic options. The chapter also includes a discussion on the emergence of immunotherapies and their advantages over current standard of care therapies.

Chapter 4 provides an introduction to cancer vaccines, including details on their history of development, respective mechanisms of action and the various challenges associated with their development and production. Further, the chapter includes brief overviews of the different types of cancer vaccines that are under development for the treatment of various oncological indications. It also includes a comprehensive compilation of the regulatory guidelines established to monitor, manage and regulate the development of therapeutic cancer vaccines.

Chapter 5 features a detailed and comprehensive analysis of the current market landscape of dendritic cell and tumor cell cancer vaccines. It includes information, such as the target indications, current phase of development, the type of donor and the type of vaccines, on the various marketed and pipeline therapies.

Chapter 6 contains a detailed discussion on dendritic cell cancer vaccines. The chapter includes detailed profiles of the marketed and phase III vaccines in this category. Each profile contains a brief discussion on the history of development of the particular therapy, its mechanism of action, dosage regimen, information on its clinical trials and key clinical insights. Further, the profiles provide details on the developer, including financial information, existing intellectual property, current product portfolio and manufacturing capabilities.

Chapter 7 provides a detailed discussion on tumor cell cancer vaccines. Similar to Chapter 6, the chapter also includes comprehensive profiles of the phase III tumor cell cancer vaccines. Each profile covers information such as the history of development of a particular therapy, its mechanism of action, dosage regimen, information on clinical trials and key clinical results. Further, it provides information about the developer as well, including details on financials, existing intellectual property, product portfolio and manufacturing facilities. In addition, this chapter consists of a case study on NewLink Genetics and its portfolio of products based on the HyperAcute® technology.

Chapter 8 includes a detailed discussion on the various technology platforms that are currently being used for the development of dendritic cell and tumor cell cancer vaccines.

Chapter 9 presents a detailed study of the investments made in this domain. The funding instances captured in the chapter include venture capital financing, public offerings, grants and other forms of equity / debt financing. The analysis highlights the growing interest of the VC community and other strategic investors in this segment of the immunotherapy market.

Chapter 10 features a comprehensive analysis of the collaborations and partnerships that have been forged between the players in this market. In the chapter, we have discussed the various types of partnership models that are employed by stakeholders in this domain. We have also categorized the deals / agreements, which we came across during our research, based on the aforementioned models and provided our reviewed the trend of partnerships over time.

Chapter 11 presents a detailed market forecast for dendritic cell and tumor cell cancer vaccines and a discussion on the overall financial opportunity that exists in this domain. It includes future sales projections for molecules in advanced stages of development. These projections took into account the target patient population, the existence of competing drugs or drug classes, likely adoption rate and the expected price of each individual therapy.

Chapter 12 provides a summary of the overall report. In this chapter, we present a list of key takeaways from the report and our independent opinion on the nature and potential of the cancer vaccines market. The insights presented in this chapter are based on the research and analysis described in the previous chapters.

Chapter 13 contains a collection of interview transcripts of discussions held with some of the key players in the industry.

Chapters 14 and 15 are appendices, which provide tabulated data and a list of companies mentioned in the report, respectively.
Note: Product cover images may vary from those shown
5 of 5
- Abramson Cancer Center
- Accelovance
- Accord Research
- Activartis Biotech
- Adaptive Biotechnologies
- Aduro Biotech
- Alliance Foundation Trials (AFT)
- American International Radio
- American Red Cross Society
- Ames Seed Capital
- Amphera
- Aptiv Solutions
- Argos Therapeutics
- Artwell Biotech
- Aspire Capital
- Asset Management Ventures
- Asterias Biotherapeutics
- Aurora BioPharma
- Aurora Funds
- AVAX Technologies
- Bar Elan University of Israel
- Basic Pharma
- Baylor College of Medicine (BCM)
- Beijing Tricision Biotherapeutics
- Benitec Biopharma
- Beth Israel Deaconess Medical Centre
- BioLife Solutions
- Biomira
- BioSante Pharmaceuticals
- BioTime
- BioTime Acquisition
- Brightline Ventures
- Bristol-Myers Squibb
- Bundang CHA General Hospital
- Caisse de dépôt et placement du Québec
- Caladrius BioSciences
- Caliber Biotherapeutics
- California Institute for Regenerative Medicine (CIRM)
- California Institute of Technology
- Canadian Brain Tumour Consortium (CBTC)
- Cancer Research Technology (CRT)
- CANCER RESEARCH UK
- Cancer Treatment Centers of America (CTCA)
- Cascadian Therapeutics
- Cedars-Sinai Medical Centre
- Cell Therapy Catapult
- Celldex Therapeutics
- Cellin Technologies
- CELLMED Research
- Champions Biotechnology
- Charles University
- Chicagoland Investors
- Chiltern International
- China BioPharma Capital I
- Chongqing Lummy Pharmaceutical
- CiMaas
- City of Hope Comprehensive Cancer Center
- Clinipace Worldwide
- Clough Capital Partners
- Cognate Bioservices
- CORFO
- CruCell
- CryoPort
- CyTuVax
- Dana Farber Cancer Center
- DanDrit Biotech
- Danube Hospital Vienna
- DCPrime
- Delta-Vir
- Dendreon Corporation
- Department of Defense (CDMRP)
- Department of Immunology of the 2nd Medical School of Charles University
- Dong-A ST
- Drexel University
- Duke University
- Dutch Ministry of Health, Welfare and Sports
- Ehime University Hospital
- Elios Therapeutics
- Emperor Franz-Josef Hospital Vienna
- ES Cell International Pte
- European Medicines Agency (EMA)
- European Organization for Research and Treatment of Cancer (EORTC)
- Feldkirch State Hospital
- Ferrer International
- FONNDEF
- Forbion Capital
- Foresite Capital Management
- Franklin Advisers
- Fraunhofer Institute for Cell Therapy and Immunology
- FUJIFILM Diosynth Biotechnologies
- Genentech
- Geron Corporation
- GISCAD Foundation
- Gradalis
- Green Cross Corporation
- GSK
- Guangzhou Trinomab Biotech
- Hakutokai Takao Hospital
- Heat Biologics
- Horizon Technology Finance Corporation
- ICON
- Immatics Biotechnologies
- Immunicum
- ImmunoCellular Therapeutics
- Immunotherapy of Cancer (ITOC)
- Innovation Agency
- Innsbruck Medical University
- Institute for Quality and Efficiency in Health Care (IQWiG)
- Institute of Inorganic Chemistry and the Institute of Chemistry of Polymers
- Intersouth Partners
- Intracel Corporation
- Invetech
- Iowa Economic Development Authority (IEDA)
- Iowa State University Research Park Corporation (ISURP)
- Janssen Pharmaceuticals
- Janus Capital Management
- Jennison Associates
- Jikei University School of Medicine
- Johannes Kepler University Linz
- Johns Hopkins University (JHU)
- Johnson & Johnson Development Corporation (JJDC)
- JW CreaGene
- Karolinska University Hospital
- King’s College Hospital
- Kirin Brewery Pharmaceutical Division
- Kiromic
- Kitasato Institute Hosptital
- Kyowa Hakko Kirin
- Laboratorio Pablo Cassara
- Leaders in Oncology Care (LOC)
- Lumira Capital
- Maastricht University Medical Centre
- Mary Crowley Cancer Research Center
- Masarik University Brno
- Massachusetts Biotechnology Council (MassBio)
- Maxim Group
- Mayo Clinic
- MD Anderson Cancer Centre
- Medical Corporation Hakutokai
- Medical Corporation Isokai
- Medical School of Charles University
- Medical University of Graz
- Medical University of Hannover
- Medical University of Vienna
- Medigene Immunotherapies
- Medinet
- Merck
- Merix Bioscience
- Midwest Melanoma Partnership (MMP)
- Mizuho capital
- MNX Global Logistics
- MolecuVax
- Morningside Group
- Morningside Ventures
- National Cancer Institute
- National Center for Global Health and Medicine
- National Center for Global Health and Medicine
- National Health Service (NHS)
- National Institute for Health and Care Excellence (NICE)
- National Institutes of Health (NIH)
- National University Corporation Kyushu University
- National University of Singapore (NUS)
- NeoStem
- Neovii Biotech
- NewLink Genetics
- Northwest Biotherapeutics
- Novartis
- NovaRx Corporation
- Novella Clinical
- Oncobiomed
- OncoSec Medical
- Oncothyreon
- OrbiMed
- Oxford Finance
- Pan Am Cancer Treatment Center
- Paul Ehrlich Institute (PEI)
- PDC*line pharma
- PerImmune
- Pfizer
- PharmaCell
- Pharmacenter Hungary
- Pharmstandard International
- Piedmont Angel Network
- Pique Therapeutics
- PPF Group
- Prima BioMed
- Progenitor Cell Therapy (PCT)
- ProImmune
- ProVaccine
- Pure MHC
- Regeneus
- Research Center for Molecular Medicine of the Austrian Academy of Sciences
- RimAsia Capital Partners
- Roche
- Rockefeller University
- Rudolfstiftung Hospital Vienna
- Sächsische Aufbau Bank
- Sahlgrenska University Hospital
- Saint-Gobain
- Salzburg Provincial Hospital
- Sarah Cannon Research UK
- Saronic Biotechnology
- School of Medicine of Keio University
- Scottish Medicines Consortium
- SDS Capital
- Shenzhen Hornetcorn Bio-technology Company
- Significo Research
- SIGNIFIX
- Socius Life Sciences Capital Group
- SOTIO
- Square 1 Bank
- St. Anna Children's Cancer Research
- Stanford University
- State Institute for Drug Control
- Swissmedic
- Sydys Corporation
- TapImmune
- Targepeutics
- Technomark Life Sciences
- tella
- Tessa Therapeutics
- The Immune Response Corporation
- The Investment Syndicate (TIS)
- The Vaccine & Gene Therapy Institute of Florida (VGTI)
- Theradex
- Therapeutic Solutions International
- TheraTest Laboratories
- TI Pharma
- Tianyi Lummy International Holdings Group
- Torrey Pines Institute for Molecular Studies
- TransCure bioServices
- Trianta Immunotherapies
- TVAX Biomedical
- TVM Capital
- UCB
- United States Food and Drug Administration (USFDA)
- United Therapeutics
- UniVax
- University Hospital Motol of Prague
- University of British Columbia
- University of Chile
- University of Maryland
- University of Minnesota
- University of Pennsylvania
- University of Pittsburgh
- University of Southern California
- University of Texas
- University of Zurich Medical School
- Uppsala University
- US Patent and Trademark Office (USPTO)
- Vaccinogen
- Valeant Pharmaceuticals
- Van Herk Group
- Västra Götalandsregionen
- Wagner-Jauregg Linz
- Wasatch Funds Trust
- Wilmington Investors Network
- Woodford Investment Management
- WuXi AppTec
- XEME Biopharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll